| [1] |
中华医学会风湿病学分会．抗磷脂综合征诊断和治疗指南 [J]. 中华风湿病学杂志，2011, 15(6): 407-410.
|
| [2] |
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [J]. J Thromb Haemost, 2006, 4(2): 295-306.
|
| [3] |
David G, Doruk E. Diagnosis and management of the antiphospholipid syndrome [J]. N Engl J Med, 2018, 378(21): 2010-2021.
|
| [4] |
Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification for definite antiphospholipid syndrome [J]. Arthritis Rheum, 1999, 42(7): 1309-1311.
|
| [5] |
Bertolaccini ML, Amengual O, Atsumi T, et al. 'Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010 [J]. Lupus, 2011, 20(2): 191-205.
|
| [6] |
Sciascia S, Amigo MC, Roccatello D, et al. Diagnosing antiphospholipid syndrome: 'extra-criteria’ manifestations and technical advances [J]. Nat Rev Rheumatol, 2017, 13(9): 548-560.
|
| [7] |
de Jesus GR, Agmon-Levin N, Andrade CA, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome [J]. Autoimmun Rev, 2014, 13(8): 795-813.
|
| [8] |
Arachchillage DR, Machin SJ, Mackie IJ, et al. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome [J]. Thromb Haemost, 2015, 113(1): 13-19.
|
| [9] |
Drozidnsky G, Hadar E, Shmueli A, et al. Obstetric antiphospholipid syndrome and long term arterial thrombosis risk [J]. J Thromb Thrombolysis, 2017, 44(3): 371-375.
|
| [10] |
Saccone G, Berghella V, Maruotti GM, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome, the PREGNANTS study [J]. Am J Obstet Gynecol, 2017, 216(5): 525.e1-525.e12.
|
| [11] |
Abrahams VM, Chamley LW, Salmon JE. Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation [J]. Arthritis Rheumatol, 2017, 69(9): 1710-1721.
|
| [12] |
Meroni P L, Crotti C, Chighizola C. Antiphospholipid antibody mechanisms of thrombosis [M]. Milan: Springer, 2015: 25-36.
|
| [13] |
Jeanette R, Carpenterand D, Ware Branch. Antiphospholipid syndrome in pregnancy [M]. In Gabbe SG, Niebyl JR, Simpson JL, et al eds. Obstetrics: Normal and Problem Pregnancies, Seventh ed. Philadelphia: Elsevier, 2017: 981-997.
|
| [14] |
Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome [J]. Nat Rev Dis Primers, 2018, 4:17103.
|
| [15] |
Mekinian A, Alijotas-Reig J, Carrat F, et al. Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicentre retrospective stud [J]. Autoimmun Rev, 2017, 16(7):730-734.
|
| [16] |
Jara LJ, Medina G, Cruzcruz P, et al. Non-criteria or seronegative obstetric antiphospholipid syndrome? [J]. Isr Med Assoc J, 2017, 19(6): 382-386.
|
| [17] |
吴淑燕，张建平. 复发性流产的抗凝治疗 [J]. 中国实用妇科与产科杂志，2017, 33(7):671-675.
|
| [18] |
Silver RM. Catastrophic antiphospholipid syndrome and pregnancy [J]. Semin Perinatol, 2018, 42(1): 26-32.
|
| [19] |
Schreiber K, Radin M, Sciascia S. Current insights in obstetric antiphospholipid syndrome [J]. Curr Opin Obstet Gynecol, 2017, 29(6): 397-403.
|
| [20] |
Andreoli L, Bertsias GK, Agmon-Levin N, et al. Extended report: EULAR recommendations for women′s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome [J]. Ann Rheum Dis, 2017, 76(3): 476-485.
|
| [21] |
Bala MM, Celinska-Lowenhoff M, Szot W, et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and otherthromboembolic events in people with antiphospholipid syndrome [J]. Cochrane Database Syst Rev, 2017, 10: CD012169.
|
| [22] |
Lefkou E, Mamopoulos A, Dagklis T, et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy [J]. J Clin Invest, 2016, 126(8): 2933-2940.
|
| [23] |
Corban MT, Duarte-Garcia A, McBane RD, et al. Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics [J]. J Am Coll Cardiol, 2017, 69(18): 2317-2330.
|
| [24] |
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome [J]. N Engl J Med, 2018, 379(13):1290.
|
| [25] |
Mekinian A, Costedoat-Chalumeau N, Masseau A, et al. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? [J] Autoimmun Rev, 2015, 14(1): 23-29.
|
| [26] |
Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review [J]. J Autoimmun, 2018, 92: 1-11.
|
| [27] |
Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction [J]. Am J Obstet Gynecol, 2018, 218(2S): S829-S840.
|
| [28] |
Ruffatti A, Hoxha A, Favaro M, et al. Additional treatments for high-risk obstetric antiphospholipid syndrome: a comprehensive review [J]. Clin Rev Allergy Immunol, 2017, 53(1): 28-39.
|
| [29] |
Cavazzana I, Andreoli L, Limper M, et al. Update on antiphospholipid syndrome: Ten Topics in 2017 [J]. Curr Rheumatol Rep, 2018, 20(3): 15.
|
| [30] |
赵爱民，低分子肝素防治自然流产中国专家共识编写组. 低分子肝素防治自然流产中国专家共识 [J]. 中华生殖与避孕杂志，2018, 38(9): 701-708.
|
| [31] |
Ye SL, Gu XK, Tao LY, et al. Efficacy of different treatment regimens for antiphospholipid syndrome-related recurrent spontaneous abortion [J]. Chin Med J (Engl), 2017, 130(12): 1395-1399.
|